FAIR-HF2: Ferric Carboxymaltose Safe With Some Benefits For Heart Failure
American College of Cardiology
MARCH 30, 2025
25 in Chicago and simultaneously published in JAMA.
Heart Failure Hospital Quality of Life 
Quality of life in heart failure. The heart of the matter. A scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology
European Journal of Heart Failure
MARCH 12, 2025
For most patients with chronic, progressive illnesses, maintaining good quality of life (QoL), with preserved functional capacity, is just as crucial as prolonging survival. These symptoms reduce patients' capacity for daily social and physical activity.
Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure
DAIC
JULY 25, 2024
BioCardia previously confirmed alignment with the United States Food and Drug Administration (FDA) on the design of the 250-patient randomized, controlled trial and the minimum of 12-month primary composite endpoint of all cause death, reduction in major adverse cardiovascular events, and improvement in quality of life.
Heart Failure 
111
111 
Allina Health’s Abbott Northwestern Hospital is First in Minnesota to Implant Barostim Therapy to Improve Symptoms of Heart Failure
DAIC
FEBRUARY 12, 2024
A team at Allina Health’s Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. I felt weak and tired all the time and knew I didn’t want to spend my life sitting in the living room chair.
Heart Failure 104
104 
M-TEER Reduces Cardiovascular Risk, Improves Quality of Life in HF with Mitral Regurgitation
HCPLive
AUGUST 31, 2024
RESHAPE-HF2 shows mitral transcatheter edge-to-edge repair (M-TEER) reduces heart failure hospitalizations and improves quality of life vs optimal medical therapy alone.
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
DAIC
MARCH 13, 2024
CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,
CMS 111
111 
Ochsner Children’s Hospital Advocates to Close the Gap in Pediatric Heart Care
DAIC
FEBRUARY 21, 2024
Getty Images milla1cf Wed, 02/21/2024 - 19:10 February 21, 2024 — Ochsner Children's Hospital , ranked among the top hospitals in the nation for pediatric cardiology and congenital heart surgery, is raising awareness of the need for more pediatric-specific heart devices.
Pediatrics 105
105 
Development and validation of a machine learning model for online predicting the risk of in heart failure: based on the routine blood test and their derived parameters
Frontiers in Cardiovascular Medicine
MARCH 16, 2025
We hope to identify high-risk patients for early intervention to reduce the incidence of HF and improve their quality of life. The patients were divided into an experimental group (HF patients) and a normal control group.
ALT-FLOW and the HF Shunt Alternative
CardiacWire
FEBRUARY 19, 2025
Although heart failure prognosis is grim, the ALT-FLOW trials two year results suggest that diverting blood from the left atrium to the coronary sinus using a shunt could have lasting benefits for patients with HFmrEF/HFpEF. By year two, this improved to 85.5% of patients experiencing class I or II symptoms.
Impact of Interatrial Shunt May Vary by Heart Failure Type
DAIC
APRIL 6, 2024
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
RELIEVE-HF Trial Outcomes Reported at ACC.24 Find Impact of Interatrial Shunt May Vary by Heart Failure Type
DAIC
APRIL 6, 2024
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
Heart Failure Patients Who Do Yoga Have Stronger Hearts and Can be More Active
DAIC
MAY 28, 2024
milla1cf Tue, 05/28/2024 - 07:00 May 28, 2024 — Yoga focused on breathing, meditation, and relaxation is linked with symptom improvement in patients with heart failure, according to research presented at Heart Failure 2024 , a scientific congress of the European Society of Cardiology (ESC).
Heart failure patients see no benefits in severe salt restriction
Becker's Hospital Review - Cardiology
JULY 9, 2024
New study finds strict sodium restrictions may not benefit heart failure patients. per day can improve quality of life Moderate salt intake of 3.0-4.5g
Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery
European Journal of Heart Failure
NOVEMBER 29, 2023
ABSTRACT Aims Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology Heart Failure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries.
Epidemiology, Pathophysiology, Diagnosis and Management of Chronic Right?Sided Heart Failure and Tricuspid Regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC
European Journal of Heart Failure
DECEMBER 22, 2023
Abstract Right-sided heart failure and tricuspid regurgitation are common and strongly associated with poor quality of life and an increased risk of heart failure hospitalizations and death. This article is protected by copyright. All rights reserved.
Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER
European Journal of Heart Failure
DECEMBER 13, 2023
ABSTRACT Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse outcomes. The primary outcome was a composite of cardiovascular death or worsening heart failure. 0.93]; COPD: HR 0.82 [95% CI 0.62–1.10];
AHN Studying an Innovation that Improves Quality of Life and Cardiac Function in Heart Failure Patients
HCPLive
MARCH 14, 2024
The AccuCinch® System, utilized by Allegheny General Hospital, offers a breakthrough approach to treating heart failure by targeting the left ventricle.
CVRx Announces Availability of Additional Data Supporting Long-term Benefits of Barostim
DAIC
APRIL 16, 2024
a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. The manuscript is available online at the European Journal of Heart Failure website.
Heart Failure 104
104 
Focus on Heart Failure | Ironclad: The Treatment of Iron Deficiency in Heart Failure
American College of Cardiology
AUGUST 2, 2024
Iron deficiency (ID) is a common comorbidity among patients with heart failure (HF), and it is associated with reduced exercise tolerance and quality of life and serves as a marker of increased risk of hospitalizations and mortality.
V-Wave to Present Late-Breaking Data from Pivotal RELIEVE-HF Study at American College of Cardiology Annual Scientific Session and Expo
DAIC
MARCH 29, 2024
The primary effectiveness endpoint was a composite of death, heart transplant/left ventricular assist device (LVAD) implantation, HF hospitalization, outpatient HF worsening, and quality of life. where it is a leading cause of death and hospitalization, i and 56.2 and worldwide," said Neal Eigler, M.D. ,
Regular exercise pre-hospitalization is linked to better outcomes in heart failure, study shows
Medical Xpress - Cardiology
MARCH 17, 2025
Heart failure is a major health concern, especially for aging populationsit significantly increases mortality rates, and severely impacts quality of life of those affected. Exercise therapy has been shown to be particularly effective for patients with heart failure.
FDA Expands Indication for Impella Heart Pumps for Pediatric Patients
DAIC
DECEMBER 18, 2024
12, 2024 Physicians have a new treatment option for many of the sickest pediatric patients with heart failure andcardiogenic shock. and Impella CP enable heart recovery as part of the world's smallest heart pump platform. with SmartAssist tim.hodson Wed, 12/18/2024 - 14:06 Dec.
Pediatrics 52
52 
Leveraging AI-Enabled Remote Cardiac Monitoring to Improve Cardiovascular Care
DAIC
FEBRUARY 24, 2025
As a result, healthcare faces rising expenses from frequent emergency room visits, lengthy hospital stays, costly procedures like stent placements and bypass surgeries, as well as the long-term management of chronic conditions like heart failure (HF). These costs represent a massive portion of total health expenditures.
Hospital 52
52 
Left Ventricular Assist Device Therapy in Cold and Dry Patients
Circulation: Heart Failure
JANUARY 8, 2025
Circulation: Heart Failure, Ahead of Print. Compared with cold and wet patients, cold and dry patients also had better baseline functional capacity and quality of life and experienced milder improvements after LVAD: EuroQol (+0.11 versus +0.17;P=0.001),
In-hospital electrical muscle stimulation for patients early after heart failure decompensation: results from a prospective randomised controlled pilot trial
Open Heart
JULY 11, 2022
Background Electrical muscle stimulation (EMS) is being evaluated as a possible alternative to exercise training to improve functional capacity in severely deconditioned patients with heart failure (HF). However, there is insufficient data on delayed effects of EMS starting early after decompensation.
Cardiac rehabilitation for heart failure and atrial fibrillation: a propensity- matched study
Open Heart
AUGUST 10, 2023
Background Atrial fibrillation (AF) is common in individuals with heart failure (HF). Individuals with HF and AF may have a reduced functional capacity and quality of life (QoL) which leads to hospital admission and burden on clinical services. Results 149 individuals were propensity matched from each group.
New Treatment in Pipeline for Patients with Hypertrophic Cardiomyopathy
DAIC
MAY 14, 2024
In about 70 percent of cases, patients with HCM experience obstruction to blood flow, which increases pressures in the heart and can lead to chest pain, shortness of breath and reduced exercise capacity. The late breaking research was presented by principal investigator Martin S. Cytokinetics Inc. provided the funding for this study.
Cardiomyopathy 126
126 
Vericiguat combined with “new quadruple” therapy enhances cardiac function and life quality in patients with heart failure: a single-center prospective study
Frontiers in Cardiovascular Medicine
OCTOBER 10, 2024
ObjectiveTo investigate the therapeutic effect of Vericiguat combined with “new quadruple” drugs on patients with heart failure (HF).MethodsFrom and improved patients’ quality of life scores.
Use of sacubitril/valsartan early after CABG
Open Heart
JANUARY 18, 2024
Background Heart failure (HF) remains a major public health problem with a high mortality and morbidity worldwide. The primary endpoint assessed the key safety outcomes, the secondary endpoints were: the quality of life measured, the N-terminal pro-B-type natriuretic peptide (NT-proBNP) changes and 6 min walk test (6MWT).
Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial
Circulation: Heart Failure
MARCH 5, 2024
Circulation: Heart Failure, Ahead of Print. The strongest independent predictors of a greater improvement in QoL were younger age (P<0.001), no HF hospitalization in the previous year (P<0.001), lower NYHA class before hospital admission (P<0.001) and high-intensity care treatment (mean difference, 4.2 [95%
New Drug Fails to Improve Diabetes-Related Heart Failure
DAIC
APRIL 9, 2024
Decline in exercise ability is a hallmark of progression to overt heart failure. These results also speak to the importance of continuing to focus on earlier recognition of heart failure risk in patients with diabetes and on initiating treatment before the condition has progressed to overt heart failure.”
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
DAIC
FEBRUARY 2, 2024
“Patients suffering with tricuspid regurgitation endure life-impairing symptoms and, until today, had no approved transcatheter treatment options,” said Susheel Kodali, MD , director, Structural Heart and Valve Center at Columbia University Irving Medical Center/New York-Presbyterian Hospital and TRISCEND II Study Principal Investigator.
Tricuspid 100
100 
Resynchronising the Heart in Heart Failure
Dr. Sanjay Gupta
MAY 23, 2022
Today’s vlog is on the subject of heart failure and in particular on a special type of pacemaker which can make a significant improvement to the quality of life and length of life in patients with heart failure. What is heart failure?
Allina Health Minneapolis Heart Institute is First in Minnesota to Implant Barostim Therapy to Improve Symptoms of Heart Failure
DAIC
FEBRUARY 12, 2024
A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. and Allina Health. and Allina Health. and Allina Health.
Abbott Announces FDA Approval of First-of-its-kind Device to Repair Leaky Tricuspid Heart Valve, TriClip
DAIC
APRIL 2, 2024
Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heart valve, for which more than 1.6 are affected by tricuspid regurgitation, 1 which can severely impact quality of life. Abbott has announced U.S million people in the U.S. are estimated to be affected. and Lynn C.
Tricuspid 105
105 
Exercise?based cardiac rehabilitation for adults with heart failure – 2023 Cochrane systematic review and meta?analysis
European Journal of Heart Failure
OCTOBER 31, 2023
This 2023 Cochrane review of 60 randomized trials in 8728 heart failure patients, confirms the benefits of participation in exercise-based cardiac rehabilitation (ExCR), including reduced risk of hospitalization and a clinically meaningful improvement in health-related quality of life.
Abstract 4138578: NICE-Support program effectively improves symptom and psychological distress in patients with heart failure
Circulation
NOVEMBER 11, 2024
Background:Patients with heart failure may suffer from symptom distress, affecting their overall quality of life and psychological well-being including depression. The control group followed routine hospital care. Circulation, Volume 150, Issue Suppl_1 , Page A4138578-A4138578, November 12, 2024.
Fine-tuning early rhythm control strategies for atrial fibrillation – Timing matters to stay in sync
HeartRhythm
MAY 2, 2024
Rhythm control with either medications or catheter ablation is an established strategy for symptomatic patients with atrial fibrillation (AF), by reducing arrhythmic burden and improving patient quality of life, as well as reducing the risk of heart failure hospitalization and mortality in select populations with concomitant AF and heart failure.
Iron deficiency and supplementation in patients with heart failure: Results from the IRON‐HF international survey
European Journal of Heart Failure
FEBRUARY 5, 2025
Aims Iron deficiency (ID) is common in patients with heart failure (HF) and is associated with poor outcomes, regardless of anaemia status. Iron supplementation has been demonstrated to improve exercise capacity and quality of life in patients with HF with an ejection fraction <50% and ID.
Implantable Cardioverter Defibrillators for Primary Prevention During or Early Following Hospitalization? A Time to Pause, Reflect and Exercise Sound Clinical Judgement.
HeartRhythm
MAY 29, 2024
Current guidelines recommend ICD implantation in individuals with symptomatic heart failure (HF) and reduced left ventricular ejection fraction (HFrEF) if they have been receiving optimal guideline directed medical therapy for at least 3-6 months and who are expected to have survival greater than one year with meaningful quality of life (1).
Preventive catheter ablation for ventricular arrhythmias in patients with end‐stage heart failure referred for heart transplantation evaluation: Rationale for and design of the CASTLE‐VT trial
European Journal of Heart Failure
NOVEMBER 11, 2024
Aims Timely referrals for transplantation and left ventricular assist device (LVAD) play a key role in favourable outcomes in patients with advanced heart failure (HF). Cardiovascular mortality, driven by sudden cardiac death, is the main reason for dying while waiting for heart transplantation (HTx).
Non?cardiac comorbidities and intensive up?titration of oral treatment in patients recently hospitalized for heart failure: Insights from the STRONG?HF trial
European Journal of Heart Failure
OCTOBER 4, 2023
CI, confidence interval; COPD, chronic obstructive pulmonary disease; HF, heart failure; HR, hazard ratio; TIA, transient ischaemic attack. The treatment effect of HIC versus UC on the primary endpoint, 180-day death or heart failure (HF) rehospitalization, was compared by NCC number and by each individual comorbidity.
Abstract 4117856: Effects of a Nurse-led Common-sense Model of Self-regulation-Based Heart Failure Self-care Program on Patient Outcomes: A Randomized Controlled Trial
Circulation
NOVEMBER 11, 2024
Introduction:Guidelines have recognized the critical role of self-care in heart failure (HF), but people with HF do not adequately practice self-care. Participants were recruited from a university-affiliated hospital and randomized at a 1:1 ratio into the intervention or the control groups.
Nursing 40
40 
Tirzepatide Improves HFpEF Symptoms and Outcomes
CardiacWire
AUGUST 2, 2024
Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preserved ejection fraction and obesity. vs. +15 KCCQ-CSS points). vs. -2.2%).
Outcomes 59
59 
Let's personalize your content